<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160102025811N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-04-05</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>weaning nasal continuous positive airway pressure (NCPAP) in premature neonates with respiratory distress syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Investigate various strategies for weaning nasal continuous positive airway pressure (NCPAP) in premature neonates with respiratory distress syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-03-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/43081</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: In this study, clinical trials of premature infants 26 to 32 weeks and six days of age with respiratory distress syndrome were born at the Al-Zahra Educational and Medical Center in Tabriz with respiratory shockorder (ACORN) 5 to 8%. They were airborne (NCPAP) (after the acute phase of the primary disease and the start of weaning with the approval of neonatal subspecialty or neonatal subspecialty assistant), the study entered and the infants were randomly divided into 3 groups by computer guidance.</study_design>
      <phase>3</phase>
      <hc_freetext>Respiratory distress syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Premature infants 26 to 32 weeks with respiratory distress syndrome, with a positive airway end pressure of 5 and an fraction of inspired oxygen of 30%,  Infants underwent respiratory support with a high flow nasal cannula at a rate of 3 liters per minute and an fraction of inspired oxygen of 30%. Intervention 2: Premature infants 26 to 32 weeks with respiratory distress syndrome, with a positive airway end pressure of 3 and an fraction of inspired oxygen of 25%,  Infants underwent respiratory support with a high flow nasal cannula at a rate of 3 liters per minute and an fraction of inspired oxygen of 25%. Intervention 3: Premature infants 26 to 32 weeks with Respiratory Distress Syndrome who gradually decreased 1 cm/H2O of positive airway pressure (PEEP) every 8 hours and when reached 3 cm/H2O positive airway pressure and fraction of inspired oxygen 25% ,infants will be located in oxygen hood with 5-6 liters per minute and fraction of inspired oxygen 30%. Intervention 4: Premature infants 26 to 32 weeks with Respiratory Distress Syndrome who gradually decreased 1 cm/H2O of positive airway pressure (PEEP) every 8 hours and when reached 3 cm/H2O positive airway pressure and fraction of inspired oxygen 25% , ventilation support will be cessated and infants will be located in room air.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is We are working on it.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mirhadi Mousavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golgasht Street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5136735886</zip>
        <telephone>+98 41 3327 2094</telephone>
        <email>drmussavihadi@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mirhadi Mousavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golgasht Street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5136735886</zip>
        <telephone>+98 41 3327 2094</telephone>
        <email>drmussavihadi@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Premature infants 26 to 32 weeks and six days with respiratory distress syndrome (premature onset of respiratory distress in the first 4 hours of life or radiographic findings in favor of respiratory distress syndrome) Positive airway pressure has been implicated in neonatal intensive care unit (NICU).</inclusion_criteria>
      <agemin>104 days</agemin>
      <agemax>224 days</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Infants with chromosomal defects
Infants with severe congenital anomalies or severe congenital heart disease
Infants with sphincter with Apgar less than 7 minutes
Infants under mechanical ventilation
Revived (advanced) babies
Babies with parental dissatisfaction with entering the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>P22.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Respiratory distress syndrome of newborn</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Premature infants 26 to 32 weeks with respiratory distress syndrome, with a positive airway end pressure of 5 and an fraction of inspired oxygen of 30%,  Infants underwent respiratory support with a high flow nasal cannula at a rate of 3 liters per minute and an fraction of inspired oxygen of 30%.</i_keyword>
      <i_keyword>Premature infants 26 to 32 weeks with respiratory distress syndrome, with a positive airway end pressure of 3 and an fraction of inspired oxygen of 25%,  Infants underwent respiratory support with a high flow nasal cannula at a rate of 3 liters per minute and an fraction of inspired oxygen of 25%.</i_keyword>
      <i_keyword>Premature infants 26 to 32 weeks with Respiratory Distress Syndrome who gradually decreased 1 cm/H2O of positive airway pressure (PEEP) every 8 hours and when reached 3 cm/H2O positive airway pressure and fraction of inspired oxygen 25% ,infants will be located in oxygen hood with 5-6 liters per minute and fraction of inspired oxygen 30%.</i_keyword>
      <i_keyword>Premature infants 26 to 32 weeks with Respiratory Distress Syndrome who gradually decreased 1 cm/H2O of positive airway pressure (PEEP) every 8 hours and when reached 3 cm/H2O positive airway pressure and fraction of inspired oxygen 25% , ventilation support will be cessated and infants will be located in room air.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Respiratory distress syndrome score. Timepoint: Prior to intervention in all study groups and daily at specified times until discontinuation of respiratory support. Method of measurement: Score based on the number of breaths, need for oxygen, retraction, moaning, breathing sounds , immaturity.</prim_outcome>
      <prim_outcome>Apnea. Timepoint: Before the intervention and at certain times daily after the intervention until the cessation of respiratory support. Method of measurement: Number of respiratory arrests per hour.</prim_outcome>
      <prim_outcome>Duration of hospitalization. Timepoint: From the beginning to the end of the patient's hospitalization. Method of measurement: Number of days spent in the hospital.</prim_outcome>
      <prim_outcome>Need to oxygen therapy. Timepoint: Before intervention and daily at specified times until discontinuation of respiratory support. Method of measurement: 10% increase in fraction of inspired oxygen(yes/no).</prim_outcome>
      <prim_outcome>Retinopathy of Prematurity. Timepoint: At 28 days of birth. Method of measurement: Ophthalmological consultation.</prim_outcome>
      <prim_outcome>Intraventricular haemorhage. Timepoint: At the end of intervention. Method of measurement: Brain sonography.</prim_outcome>
      <prim_outcome>Respiratory Distress Syndrome. Timepoint: at the end of intervention. Method of measurement: Need oxygen after discharge.</prim_outcome>
      <prim_outcome>Mortallity. Timepoint: At the end of intervention. Method of measurement: Neonate death.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-03-27</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Av.Azadi,  Av.Golgasht Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
